Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436.SH) Latest Company News

Oct 30, 2026, 09:47 UTC
Zhangzhou Pien Tze Huang Pharmaceutical reported third-quarter net profit of RMB 194.7 million.
Source:
- finance.sina.cn
Oct 16, 2026, 11:02 UTC
Pien Tze Huang disclosed 2024 remuneration and 2022–2024 term-incentive income for five directors and senior executives following final assessment by the Zhangzhou State-owned Assets Supervision and Administration Commission.
Source:
- finance.sina.cn
Oct 13, 2026, 11:00 UTC
Zhangzhou Pien Tze Huang Pharmaceutical announced that chairman Lin Zhihui resigned as chairman, director, legal representative and committee member due to a work adjustment, effective upon delivery of his resignation to the board.
Source:
- finance.sina.cn
Sep 22, 2026, 11:19 UTC
Pien Tze Huang appointed Shi Yixiong as its general manager and proposed adding him as a non-independent director candidate of the seventh board.
Source:
- finance.sina.cn
Sep 3, 2026, 19:26 UTC
Pien Tze Huang's liver disease drug revenue fell about 19% year-on-year to 2.348 billion yuan in the first half of 2026.
Source:
- news.sina.com.cn
Sep 3, 2026, 19:26 UTC
Pien Tze Huang reported second-quarter 2026 revenue of 1.832 billion yuan, down 18.12% year-on-year, and net profit attributable to shareholders of 349 million yuan, down 21.02%.
Source:
- news.sina.com.cn
Aug 28, 2026, 09:18 UTC
Pien Tze Huang announced its first-half 2026 results: revenue of 4.573 billion yuan, down 14.98% year-on-year; net profit attributable to shareholders of 1.093 billion yuan, down 24.22% year-on-year; non-GAAP net profit of 1.055 billion yuan, down 27.41% year-on-year.
Source:
- finance.sina.cn
- news.sina.com.cn
Aug 28, 2026, 09:18 UTC
Pien Tze Huang proposed a cash dividend of 10.7 yuan per 10 shares, totaling 646 million yuan.
Source:
Jul 29, 2026, 10:10 UTC
Pian Zai Huang director and general manager Huang Jinming resigned on July 29, 2026 due to reaching the statutory retirement age, and will no longer hold any position in the company or its subsidiaries after leaving.
Source:
- finance.sina.cn

600436.SH

Zhangzhou Pien Tze Huang Pharmaceutical reported third-quarter net profit of RMB 194.7 million.

Pien Tze Huang disclosed 2024 remuneration and 2022–2024 term-incentive income for five directors and senior executives following final assessment by the Zhangzhou State-owned Assets Supervision and Administration Commission.

Zhangzhou Pien Tze Huang Pharmaceutical announced that chairman Lin Zhihui resigned as chairman, director, legal representative and committee member due to a work adjustment, effective upon delivery of his resignation to the board.

Pien Tze Huang appointed Shi Yixiong as its general manager and proposed adding him as a non-independent director candidate of the seventh board.

Pien Tze Huang's liver disease drug revenue fell about 19% year-on-year to 2.348 billion yuan in the first half of 2026.

Pien Tze Huang reported second-quarter 2026 revenue of 1.832 billion yuan, down 18.12% year-on-year, and net profit attributable to shareholders of 349 million yuan, down 21.02%.

Pien Tze Huang announced its first-half 2026 results: revenue of 4.573 billion yuan, down 14.98% year-on-year; net profit attributable to shareholders of 1.093 billion yuan, down 24.22% year-on-year; non-GAAP net profit of 1.055 billion yuan, down 27.41% year-on-year.

Pien Tze Huang proposed a cash dividend of 10.7 yuan per 10 shares, totaling 646 million yuan.

Pian Zai Huang director and general manager Huang Jinming resigned on July 29, 2026 due to reaching the statutory retirement age, and will no longer hold any position in the company or its subsidiaries after leaving.